Trial · NCT07911384
Brain-Machine Interface With Virtual Reality and Neuromuscular Electrical Stimulation for Upper Limb Rehabilitation After Stroke
NCT07911384, Not applicable, Not yet recruiting, Marta Sofia Ramos Torres
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Brain-Machine Interface With Virtual Reality and Neuromuscular Electrical Stimulation for Upper Limb Rehabilitation After Stroke. Trials, record NCT07911384. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911384
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brain-Machine Interface With Virtual Reality and Neuromuscular Electrical Stimulation for Upper Limb Rehabilitation After Stroke
- NCT number
- NCT07911384
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 68 participants, estimated
- Lead sponsor
- Marta Sofia Ramos Torres
- Conditions
- Ischemic Stroke
- Interventions
- Brain-Machine Interface Training With Virtual Reality and NMES, Neuromuscular Electrical Stimulation
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Fugl-Meyer Assessment for the Upper Extremity (FM-UE) Score | Baseline (T0) and immediately after the 4-week intervention (T1) | Change in upper limb motor impairment assessed using the Fugl-Meyer Assessment for the Upper Extremity (FM-UE). Scores range from 0 to 66, with higher scores indicating better motor function. The outcome is calculated as the post-intervention score minus the baseline score. |
| Secondary | Change in Action Research Arm Test (ARAT) Score | Baseline (T0) and immediately after the 4-week intervention (T1) | Change in upper limb activity assessed using the Action Research Arm Test (ARAT). The test evaluates grasp, grip, pinch, and gross movement. Total scores range from 0 to 57, with higher scores indicating better upper limb performance. The outcome is calculated as the post-intervention score minus the baseline score. |
| Secondary | Change in Wrist and Finger Extensor Muscle Strength (MRC Scale) | Baseline (T0) and immediately after the 4-week intervention (T1) | Change in muscle strength of the affected wrist and finger extensors, assessed using the Medical Research Council (MRC) scale. Each muscle group is graded from 0 (no visible or palpable contraction) to 5 (normal strength), with higher grades indicating greater muscle strength. Changes from baseline to post-intervention will be assessed. |
| Secondary | Change in Functional Independence Measure (FIM) Total Score | Baseline (T0) and immediately after the 4-week intervention (T1) | Change in functional independence assessed using the Functional Independence Measure (FIM). The scale comprises 18 items evaluating motor and cognitive aspects of daily functioning. Total scores range from 18 to 126, with higher scores indicating greater functional independence. The outcome is calculated as the post-intervention score minus the baseline score. |
| Other | Change in EEG Laterality Index (Exploratory) | Baseline (T0) and immediately after the 4-week intervention (T1) | Exploratory assessment of changes in hemispheric asymmetry of motor-related EEG activity, using a laterality index derived from electrodes C3 and C4 during motor imagery or attempted movement. This is an EEG-derived physiological index rather than a clinical rating scale. Its interpretation depends on the direction and magnitude of hemispheric asymmetry, rather than higher values necessarily indicating better or worse clinical outcomes. |
| Other | Change in Spasticity (Modified Ashworth Scale) | Baseline (T0) and immediately after the 4-week intervention (T1) | Exploratory assessment of changes in spasticity of the affected upper limb using the Modified Ashworth Scale (MAS), which grades resistance to passive muscle stretch during rapid passive movement. Scores range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate grade of 1+. Higher grades indicate greater resistance to passive movement. |
| Other | Presence of Neuropathic Pain Assessed by Routine Clinical Evaluation | Baseline (T0) and immediately after the 4-week intervention (T1) | Exploratory assessment of the presence or absence of neuropathic pain following stroke. Neuropathic pain will be assessed through routine clinical evaluation during inpatient rehabilitation. Patients are regularly questioned about the presence of pain and its characteristics, including symptoms suggestive of neuropathic pain. Based on this clinical assessment, neuropathic pain will be recorded as a binary variable (present or absent) at baseline and immediately after the intervention. No specific neuropathic pain questionnaire or diagnostic scale will be used. |
| Other | Stroke Impact Scale (SIS) Score | Immediately after the 4-week intervention (T1) | Exploratory assessment of patient-reported stroke impact using the Stroke Impact Scale (SIS), a multidimensional questionnaire evaluating physical function, cognition, communication, emotion, memory, participation, and perceived recovery. Domain scores are transformed to a 0-100 scale, with higher scores generally indicating better outcomes. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911384
GET https://conductscience.org/api/trials/v1/NCT07911384/registered